Loading
companiesCompany
RadioMedix
RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.
Overview
RadioMedix, based in Houston, is developing AlphaMedix, or 212Pb-DOTAMTATE, with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation. AlphaMedix met all primary efficacy endpoints in phase 2, with a 60 percent objective response rate in PRRT-naive gastroenteropancreatic neuroendocrine tumour patients reported at ESMO 2025, was licensed to Sanofi with Orano Med in 2024, and has its next trial planned for late 2026; the company marked twenty years at SNMMI 2026. OnCo links it to neuroendocrine tumours, to targeted alpha therapy and peptide receptor radionuclide therapy, to somatostatin receptor 2 as a target, and to Orano Med and Sanofi. Whether a lead-212 alpha emitter beats existing beta-emitter PRRT in a randomised trial is the open question. 212Pb-DOTAMTATE has its own page.
Headquarters
Houston, TX, US
Scorecard
All companies#451of 1244 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-09-12 | RadioMedix to Sanofi AlphaMedix (lead-212 DOTAMTATE), targeted alpha therapy for neuroendocrine tumours | Licence | not disclosed | not disclosed | source |
Manufacturing
Capacity map- Orano Med Plano Plano, Texas, US · Orano MedRadioisotope production, Radiopharmaceutical manufacturing
Website
Phase 2Targeted alpha therapy (lead-212)
212Pb-DOTAMTATE · AlphaMedix
An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.
Similar pages
- PairingBeta PRRT → alpha PRRT
Shares ALPHAMEDIX-02, 212Pb-DOTAMTATE, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares ALPHAMEDIX-02, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- PairingSSTR PET → PRRT
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- TechnologyActinium-225 supply: thorium stocks, accelerators and radium targets
Shares 212Pb-DOTAMTATE, Orano Med, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), Targeted alpha therapy.
- CompanyITM Isotope Technologies Munich
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- TechnologySomatostatin receptor PET (68Ga/64Cu-DOTATATE)
Shares Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaFund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211
Shares Orano Med, Targeted alpha therapy.
cancers
fronts
technologies
targets
drugs
Phase 2Targeted alpha therapy (lead-212)
212Pb-DOTAMTATE · AlphaMedix